If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Weight-loss medications like the popular versions made by Denmark's Novo Nordisk A/S (CSE:NOVOb) and US peer Eli Lilly ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

Zealand Pharma is working on the next-gen weight-loss treatment. Its Petrelintide showed promising results in a Phase 1b ...